IRIS International has changed the name of its recently acquired AlliedPath laboratory (CLIA-Lab) to Arista Laboratories, as part of its plans to build an esoteric testing laboratory focused on personalized medicine.
IRIS is a manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, and a provider of personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory.
IRIS International chairman, president and chief executive officer Cesar Garcia said that the name change from AlliedPath to Arista Laboratories, a new wholly-owned subsidiary of IRIS, is in keeping with their vision of building a esoteric testing and services laboratory focused on personalised medicine to aid in the diagnosis and treatment of disease.
“Arista Laboratories positions IRIS with the immediate infrastructure of a fully equipped high-complexity CLIA-certified laboratory offering differentiated, high value molecular diagnostics testing and molecular pathology services focused on cancer,” Garcia said.
“In addition to be being a source of anticipated additional revenue and earnings, it provides a direct commercial distribution channel for accelerating our NADiA ultra-sensitive nucleic acid detection immunoassay platform, beginning with NADiA ProsVue, a prostate cancer prognostic test, which is currently under FDA review.
“This enables us to control all aspects of commercial operations for NADiA’s planned platform launch including value-based pricing, interaction with third party payors and the ability to accelerate marketing and communication efforts.”